Innovage Holding Corp. (INNV)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$11.03+4.85%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
InnovAge raised its 2026 revenue guidance to about $975 million. Revenue grew from $221 million in 2025-Q4 to $252 million in 2026-Q3. The company hired a new President and COO to improve leadership. Adjusted EBITDA guidance was raised to $90 million, showing better operations.
Operating income is still negative and got worse in 2026-Q3. The company is loss-making and profit margins are weak. Leadership changes have not yet improved financial results.
The price is about 46% above our fair value near $8. Analysts expect 9% revenue growth, which we think is fair.
Breaks if: Adjusted EBITDA falls below $85 million in fiscal 2026
Raise full year fiscal 2026 Adjusted EBITDA guidance reflecting improved operational performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is intact, supported by strong recent financial performance, but the company is still navigating challenges related to profitability and market conditions.
The market appears to be pricing in a durable premium compared to peers, reflecting a significant expectations gap. However, the valuation is considered unjustified given the company's loss-making status and recent volatility.
Management has been focused on raising revenue and adjusted EBITDA guidance, with recent results showing strong revenue growth. However, operating income has fluctuated, indicating mixed performance and potential risks in the near term.
The long-term thesis hinges on the ability of management to maintain revenue growth and improve profitability while navigating sector trends. Key factors include guidance updates from management and performance of sector bellwethers, which could influence market sentiment.
The most important moves since the prior daily snapshot.
Company momentum fell by 80.0 points (from 50.6 to -29.4) after fresh earnings.
Composite insight fell by 15.1 points (from 12.4 to -2.7) after fresh earnings.
Signal changed from 'mild_favorable' to 'mixed' after fresh earnings.
Mixed, the news cuts both ways. The company raised its fiscal 2026 revenue guidance, which supports the read. However, the latest earnings report showed a miss, which threatens the outlook.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Key executive roles remain unfilled or unstable past mid-2026
Appoint Jennifer Browne as President and Chief Operating Officer to strengthen operational execution and growth.
Newly stated in 2026-Q1. Management appointed Jennifer Browne as President and COO effective June 8, 2026, emphasizing focus on operational rigor and growth. No financial metrics directly tied yet, so delivery assessment is pending.
“Jennifer Browne appointed as President and Chief Operating Officer, effective June 8, 2026.”
Breaks if: Fiscal 2026 revenue falls below $925 million
Continue to grow total revenues and raise full year fiscal 2026 revenue guidance based on year-to-date performance.
Stated as a priority in 3 of last 3 quarters. Total revenues increased approximately 15.9% from $853.7 million in 2025 to $989.7 million in 2026. Management raised fiscal 2026 revenue guidance twice, from $900-$950 million in 2025-Q4 to $925-$950 million in 2026-Q1, then to $950-$975 million in 2026-Q2. The trajectory is delivering with consistent revenue growth and upward guidance revisions.
“Based on our performance year to date, we are raising our fiscal 2026 revenue and Adjusted EBITDA guidance.”
“InnovAge is raising full year fiscal 2026 financial guidance... Total revenues $ 925 $ 950 million.”
“InnovAge is confirming the following financial guidance. Total revenues $ 900 $ 950 million.”
Overall, INNV's trajectory is shaped by a mix of strong recent performance and ongoing risks. Not investment advice.
as of 2026-09-09